BUZZ-Ultragenyx profits from selling a U.S. FDA voucher worth $210 millions
路透社2026/10/07 14:16October 7 - ** Pharmaceutical company Ultragenyx Pharmaceutical (RARE.O) shares rose 2.8% to $14.87 ** Ultragenyx agreed to sell an FDA priority review voucher for $210 million in cash ** The company received the voucher after FDA approval of its drug Genglycos (link) for treating Glycogen Storage Disease Type Ia (also known as von Gierke disease) ** According to the licensing agreement, upon completion of the transaction, Ultragenyx will pay 20% of the voucher sale proceeds to the U.S. National Institutes of Health ** In response to Reuters’ inquiry about the buyer, Ultragenyx has not yet replied ** The recommended retail price per patient for Genglycos in the U.S. is $2.7 million ** As of the previous trading day’s close, the stock had fallen about 35% year to date (In order to facilitate non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may be erroneous or lack required context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for the convenience of readers. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation tools.)
October 7 - ** Pharmaceutical company Ultragenyx Pharmaceutical (RARE.O) shares rose 2.8% to $14.87
** Ultragenyx agreed to sell an FDA priority review voucher for $210 million in cash
** The company obtained this voucher after the FDA approved its drug Genglycos (link) for the treatment of type Ia glycogen storage disease (also known as Von Gierke disease)
** According to the licensing agreement, after the deal is completed, Ultragenyx will pay 20% of the voucher sale proceeds to the U.S. National Institutes of Health
** In response to Reuters’ inquiry about the buyer, Ultragenyx has not yet responded
** The recommended retail price of Genglycos in the United States is $2.7 million per patient
** As of the close of the previous trading day, the stock had fallen about 35% year to date
(To support non-native English speakers, Reuters automatically translates its reports into several other languages. Automated translation may be inaccurate or lack necessary context, and Reuters does not guarantee the accuracy of the translated text. The automated translations are provided solely for reader convenience. Reuters accepts no responsibility for any harm or loss caused by the use of its automated translation service.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
“Old ginger is spicier”! Outperforming semiconductors and debt panic, post-Buffett era Berkshire (BRK.A.US) hits another record high
Berkshire Hathaway Class B shares rose as much as 3.2% to $543.06 intraday on Wednesday, marking a new all-time high since May 2, 2025. After Buffett announced his resignation a year ago, the stock price fell for several months; now, the market has set a new record high, representing its first valuation of the "post-Buffett era."
BIS closed-door meeting sends message to Wall Street: No signs of “systemic risks” from AI
At a closed-door Wall Street meeting with ticket prices starting at $7,500 and no media access, U.S. Treasury Secretary Bessent stated that she does not see any “systemic issues” with AI, refuting bubble concerns by saying, “This isn’t Pets.com.” She added that those betting on AI are “the smartest people in the world.” These comments come at a sensitive time as AI stocks have seen multiple bouts of volatility recently.
Tail risks before the US midterm elections
Crypto prices
More
